Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 6,214 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 6,214 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $22.15, for a total value of $137,640.10. Following the sale, the insider owned 21,479 shares of the company’s stock, valued at $475,759.85. This represents a 22.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of Castle Biosciences stock opened at $19.04 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 6.53. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $44.28. The business’s 50 day simple moving average is $24.93 and its two-hundred day simple moving average is $32.09. The stock has a market capitalization of $577.48 million, a P/E ratio of -43.27 and a beta of 1.11.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.49) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.49). Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%.The firm had revenue of $84.23 million during the quarter, compared to analyst estimates of $79.23 million. Analysts forecast that Castle Biosciences, Inc. will post -1.4 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Lake Street Capital boosted their price objective on shares of Castle Biosciences from $35.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Morgan Stanley upgraded shares of Castle Biosciences to a “buy” rating in a report on Monday, March 2nd. Guggenheim raised their target price on Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Zacks Research upgraded Castle Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, April 27th. Finally, Weiss Ratings lowered Castle Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Castle Biosciences has an average rating of “Moderate Buy” and an average target price of $46.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CSTL. Amundi boosted its holdings in Castle Biosciences by 15,811.5% in the first quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after acquiring an additional 4,111 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Castle Biosciences by 548.9% during the first quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock valued at $2,743,000 after acquiring an additional 115,907 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Castle Biosciences by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after purchasing an additional 655 shares during the last quarter. Jones Financial Companies Lllp raised its position in shares of Castle Biosciences by 10,592.0% in the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after purchasing an additional 2,648 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in Castle Biosciences by 34.7% in the 2nd quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock worth $713,000 after purchasing an additional 8,992 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.